# Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Canonical URL: https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-64-5-million-contract-modification-for-batr-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy
Ticker: EBS
Company: Emergent BioSolutions
Source: Emergent BioSolutions
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.emergentbiosolutions.com
## Summary

GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States

## Article Body
GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States
## Recent Company News
- 2026-06-29 13:13 EST — [Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government](https://biopharmsignal.com/news/EBS/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-e7168b1d) — Source: Emergent BioSolutions
- 2026-06-25 13:46 EST — [Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose](https://biopharmsignal.com/news/EBS/emergent-biosolutions-supports-victoria-s-voice-foundation-s-national-naloxone-awareness-day-to-help-save-lives-from-opioid-overdose) — Source: Emergent BioSolutions
- 2026-06-25 13:46 EST — [Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-64-5-million-contract-modification-for-batr-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy) — Source: Emergent BioSolutions
- 2026-06-25 13:46 EST — [Emergent BioSolutions to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/EBS/emergent-biosolutions-to-participate-in-upcoming-investor-conferences) — Source: Emergent BioSolutions
- 2026-06-25 13:46 EST — [Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-saudi-food-and-drug-authority-approval-for-acam2000r-smallpox-and-mpox-vaccinia-vaccine-live) — Source: Emergent BioSolutions
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)